The Effects of Risperidone and Olanzapine on Thinking

This study has been completed.
Janssen, LP
Information provided by:
VA Office of Research and Development Identifier:
First received: April 14, 2005
Last updated: January 20, 2009
Last verified: September 2007

The goal of this research is to find ways to maximize the benefits of antipsychotic medications for cognition.

Hypothesis: Risperidone and olanzapine will show greater benefits than conventional medications on assessments of social cognition, particularly affect perception and social perception.

Condition Intervention Phase
Psychotic Disorders
Drug: Risperidone
Drug: Olanzapine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Cognitive Effects of Risperidone and Olanzapine

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Study Start Date: October 2003
Estimated Study Completion Date: March 2006

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with schizophrenia disorder by a DSM IV.
  • Competent to sign informed consent
  • No history of poor response to Risperdal and Zyprexa
  • No organic brain disease

Exclusion Criteria:

  • Mental retardation or any chronic medical illness which results in the patient not being appropriate for a switch to Risperdal or Zyprexa.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00108368

United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073
Sponsors and Collaborators
VA Office of Research and Development
Janssen, LP
  More Information

No publications provided by VA Office of Research and Development

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00108368     History of Changes
Other Study ID Numbers: MHBS-057-00S
Study First Received: April 14, 2005
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Keywords provided by VA Office of Research and Development:
antipsychotic medication
information processing
social cognition

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features
Antipsychotic Agents
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents processed this record on November 27, 2015